CLINUVEL Receives EMA Scientific Advice for Pivotal Phase III Vitiligo Study Using "Totality of Evidence" Approach
核心洞察
CLINUVEL received final EMA scientific advice for its pivotal Phase III CUV107 study evaluating SCENESSE (afamelanotide) as a systemic vitiligo (搜索) treatment, with the agency endorsing a "totality of evidence" regulatory approach.
The 300-patient study will compare SCENESSE plus narrowband UVB therapy versus NB-UVB monotherapy alone, using T-VASI50 as the primary endpoint and central photographic review for objective assessment.
EMA emphasized that patients with darker skin types (Fitzpatrick IV-VI) would benefit most from systemic treatment due to higher disease visibility, with patient-reported outcomes playing a crucial role in final evaluation.
CLINUVEL PHARMACEUTICALS announced that the European Medicines Agency (搜索) (EMA) has provided final scientific advice on the design of its planned pivotal Phase III CUV107 study evaluating SCENESSE (afamelanotide) as a systemic vitiligo (搜索) treatment. Following over 12 months of interaction with the EMA's Scientific Advice Working Party and Committee for Medicinal Products for Human Use, the agency endorsed a "totality of evidence" regulatory approach that could streamline the path to European approval.
Regulatory Framework and Study Design
The EMA proposed to evaluate SCENESSE's efficacy in vitiligo (搜索) using T-VASI50 as the primary endpoint, while incorporating patient-reported outcomes and clinical data from previous vitiligo studies with SCENESSE for final analyses of efficacy and safety. The agency emphasized that assessment by vitiligo patients themselves would play an important role in the final evaluation when data from CUV107 and previous studies are submitted for marketing authorization.
Central photographic review will be used to assess both primary and secondary endpoints, T-VASI50 and F-VASI75, with an array of other related secondary objectives. The study design integrates five patient and physician surveys to record Patient Reported Outcomes, reflecting the agency's emphasis on capturing both visible and patient-valued outcomes.
Study Population and Clinical Rationale
The Phase III CUV107 study will enroll 300 adults and adolescents with non-segmental vitiligo (搜索), comparing afamelanotide plus adjunct narrowband UVB therapy to NB-UVB monotherapy. The EMA advised that patients with darker skin colors (Fitzpatrick IV-V-VI) would benefit from systemic treatment first, since the visibility of disease due to the contrast between unaffected skin and vitiligo lesions is most pronounced in these patient groups.
Dr. Emilie Rodenburger, CLINUVEL's Director of Global Clinical Affairs, noted that "the patient population of darker skin complexion will be the first to benefit from a systemic treatment," highlighting a key strategic focus for the program.
Clinical Significance and Market Context
Vitiligo (搜索) affects an estimated 0.5%-2% of the general population, with no approved therapies currently available for patients with extensive depigmentation affecting more than 10% of total body surface area. The condition is believed to be a multifactorial disorder with immune components in some cases, resulting in progressive loss of pigment and severe impact on quality of life.
CLINUVEL's approach represents a strategic move into the systemic space in a field where approved therapies largely address limited body surface area through topical mechanisms. By pairing afamelanotide with NB-UVB, the program grounds itself in an accepted standard while aiming to demonstrate additive benefit over an active comparator.
Operational Considerations
The study design presents significant operational challenges, requiring centralized photographic adjudication with rigorous imaging protocols, calibrated lighting, and training to minimize variability across geographies and skin tones. Sites will need both NB-UVB capacity for frequent visits and implant administration capability for afamelanotide, adding procedural complexity to phototherapy workflows.
The emphasis on recruiting patients with skin-of-color representation, historically a bottleneck in dermatology trials, will require careful site selection and community engagement strategies aligned with the study's demographic targets.
Timeline and Next Steps
The CUV107 study is scheduled to commence in the second half of 2026. Dr. Rodenburger concluded that the extensive dialogue resulted in "a one-off position taken by the Agency, who are now fully across the SCENESSE program and possible expected outcomes in vitiligo (搜索)."
The "totality of evidence" approach gives CLINUVEL latitude to leverage earlier trials and patient-reported outcome signals rather than relying solely on a single numeric threshold, potentially de-risking the regulatory dossier if the Phase III delivers consistent, multi-source efficacy data. This framework could establish a template for future systemic vitiligo (搜索) trials that emphasize integrated evidence over single-point endpoints.